TAMARA HUNTER: Open Payments
NPI 1912285008 · ATHENS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$939 in 35 payments from 12 companies in 2025. Trend: 2023 $19 · 2024 $770 · 2025 $939
Food & beverage: $905Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $245 |
| ARS Pharmaceuticals Operations, Inc. | 10 | $164 |
| GENZYME CORPORATION | 3 | $128 |
| Novartis Pharmaceuticals Corporation | 4 | $91 |
| Amgen Inc. | 3 | $68 |
| Grifols USA, LLC | 3 | $55 |
| GlaxoSmithKline, LLC. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| CSL Behring | 1 | $31 |
| Octapharma USA, Inc. | 1 | $30 |
Products named: TEZSPIRE, NEFFY, Xembify, Rhapsido, NUCALA, AYVAKIT, DUPIXENT, Hizentra.
Industry payments across GA — which companies pay providers there.
